Stockwinners Market Radar for September 05, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

Settings & Search

CVS...		Hot Stocks 20:06 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. CVS Health (CVS) and Signify Health (SGFY) have entered into a definitive agreement under which CVS Health will acquire Signify Health for $30.50 per share in cash, representing a total transaction value of approximately $8 billion. Following the close of the transaction, Kyle Armbrester will continue to lead Signify Health as part of CVS Health. CVS Health and Signify Health anticipate that the transaction will close in the first half of 2023. 2. Volkswagen (VWAGY) said Monday that it would list its iconic sports car maker Porsche (POAHY) in one of the biggest initial public offerings in years and a crucial test of investors' confidence as high inflation and the war in Ukraine put a damper on the global economy, The Wall Street Journal's William Boston reported. The offering could value Porsche at as much as $84 billion, according to analyst estimates, injecting fresh cash into VW's coffers that executives say will help the company bankroll its transition to electric vehicles and self-driving cars, the author wrote. The German auto maker intends to list Porsche on the Frankfurt Stock Exchange and offer 25% of Porsche's preferred stock to private investors in a public offering aimed for late September or early October. 3. It seems everything that could go wrong for Target (TGT) has gone wrong this year, Teresa Rivas wrote in this week's edition of Barron's. But with Target's shares down 29% in 2022, compared with the S&P 500 index's 18% decline, a lot of the bad news is already reflected in the price of Target stock, the author argued. At the same time, there's still a lot to like about the big retailer, from its growing market share to its ever-expanding dividend. Yes, things have gone from bad to worse as Target aggressively discounts overstocked merchandise, but now its shares look like a bargain-but a bargain, it must be cautioned, best suited for investors comfortable with a bumpy road to redemption, the publication added. 4. U.S. life sciences company Illumina (ILMN) is in talks with European Union antitrust regulators to divest Grail ahead of an expected EU veto next week of its $7.1 billion acquisition of the biotechnology company, Reuters' Foo Yun Chee reported, citing people familiar with the matter. The European Commission is set to block the deal because remedies offered by Illumina do not fully address the EU competition enforcer's concerns, other sources told Reuters last month. 5. Imperial Brands (IMBBY) and Sixth Street (TSLX) saw positive mentions in this week's edition of Barron's.
CVS SGFY		Hot Stocks 17:07 EDT CVS Health to acquire Signify Health for $30.50 per share - CVS Health (CVS) and Signify Health (SGFY) have entered into a definitive agreement under which CVS Health will acquire Signify Health for $30.50 per share in cash, representing a total transaction value of approximately $8 billion. Following the close of the transaction, Kyle Armbrester will continue to lead Signify Health as part of CVS Health. CVS Health expects to fund the transaction with existing cash from its balance sheet and available resources and is committed to maintaining its current credit ratings. The transaction was approved by the Board of Directors at each of the respective companies. It is subject to approval by a majority of Signify Health's stockholders, receipt of regulatory approval and satisfaction of other customary closing conditions. Private equity funds affiliated with New Mountain Capital, which owns approximately 60% of the common stock of Signify Health, have agreed to vote the shares they own in favor of the transaction, subject to customary exceptions. CVS Health and Signify Health anticipate that the transaction will close in the first half of 2023.
BQ		Hot Stocks 09:16 EDT Boqii announces reignition of Chief Strategy Officer Kai Fang - Boqii Holding Limited announced that Kai Fang has resigned from his position as the company's Chief Strategy Officer and all his roles as a director or an officer of the applicable affiliates of the company due to personal reasons. Kai Fang has served as the company's Chief Strategy Officer since 2021.
REGN SNY		Hot Stocks 09:15 EDT Regeneron, Sanofi says Dupixent showed lung function improvement in asthma - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced results from a Phase 3 open-label extension trial demonstrating the efficacy and safety profile of Dupixent as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation. The results are from data in children who entered the extension trial after finishing active treatment or placebo in the Phase 3 trial. Children in the extension trial were treated for up to an additional year with Dupixent, providing up to two years of data in total. Children treated with Dupixent in the extension trial experienced a: Low rate of severe asthma attacks with an average of 0.118-0.124 events per year, compared to 2.16-2.56 events per year at baseline in the pivotal trial; Sustained improvement in lung function at 52 weeks of 9.43-12.6 percentage points from baseline in the pivotal trial, measured by percent predicted FEV1 Children who switched from placebo in the pivotal trial to Dupixent in the extension trial demonstrated improvement of 8.71 percentage points in lung function at two weeks. The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved respiratory indications.
AZN		Hot Stocks 09:13 EDT AstraZeneca confirms U.S. approval of Imfinzi for biliary tract cancer - AstraZeneca confirmed that Imfinzi has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy. The approval was granted after securing Priority Review and Orphan Drug Designation for Imfinzi in the U.S. in this setting. Regulatory applications are also currently under review in Europe, Japan and several other countries based on the TOPAZ-1 results, AstraZeneca added.
DVN		Hot Stocks 09:09 EDT Devon, Delfin enter liquefied natural gas export partnership - Delfin Midstream and Devon Energy (DVN) announced that they have entered into a liquefied natural gas export partnership that includes an executed Heads of Agreement for long-term liquefaction capacity and a pre-Financial Investment Decision strategic investment by Devon in Delfin. The HOA provides the framework for finalizing a definitive long-term tolling agreement representing 1.0M tons per annum of liquefaction capacity in Delfin's first Floating LNG vessel, with the ability to add an additional 1.0 MTPA in Delfin's first or a future Floating LNG vessel. In addition to providing Devon up to 2.0 MTPA of total liquefaction capacity on a long-term basis, the HOA also provides opportunity for additional future equity investments in Delfin by Devon. Devon's 2022 guidance will remain unchanged. "Our decision to invest in Delfin was the result of a thorough process intended to create additional pricing diversification for our natural gas portfolio and deliver a sustainable and capital efficient return for our shareholders," said Rick Muncrief, Devon's CEO. "Devon has a strong track record of finding best-in-class midstream and downstream solutions for our production and we are excited to partner with Delfin to meet the need for safe, clean and reliable energy."
LPTX BGNE		Hot Stocks 09:07 EDT Leap Therapeutics presents DisTinGuish results for DKN-01 plus Tislelizumab - Leap Therapeutics (LPTX) announced the company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 antibody, DKN-01, in combination with tislelizumab, BeiGene's (BGNE) anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology Congress 2022 being held on September 9-12. DKN-01 and tislelizumab plus CAPOX was well tolerated in first-line treatment for advanced GEA patients, with a safety profile consistent with previous reports; Overall median progression-free-survival of 11.3 months exceeds benchmark results in unselected patients and in all four important biomarker-directed subgroups; Median overall survival is not mature with only 44% of patients deceased as of the data cut, with a median duration on study of 15.7 months and last patient enrolled in early April 2021, Leap said in a statement.
ZYME		Hot Stocks 09:05 EDT Zymeworks announces abstract from Phase 1 study of zanidatamab zovodotin - Zymeworks announced the release of an abstract by ESMO with preliminary results from the company's Phase 1 study of zanidatamab zovodotin, an investigational novel bispecific HER2 targeted antibody-drug conjugate. In an ongoing Phase 1 study of 76 patients with HER2+ cancers including gastric and breast cancers, preliminary results show that the majority of treatment related adverse events were Grade 1 or 2 and included keratitis, alopecia and diarrhea. Among seven patients who experienced TRAEs of grade 3 or higher, two were grade 4 events including infusion-related reaction and decreased neutrophil count. There were three patient discontinuations associated with TRAEs and no reported treatment-related patient deaths or cases of interstitial lung disease. "Results also showed encouraging single-agent anti-tumor activity in heavily pretreated patients with HER2+ cancers, including a confirmed objective response rate of 28% and a disease control rate of 72% in 29 patients treated at a dose of 2.5 mg/kg on an every three week (Q3W) schedule," Zymeworks said in a statement.
GILD		Hot Stocks 09:03 EDT Gilead says Trodelvy showed benefit regardless of HER2 status in study - Gilead Sciences announced new data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy versus comparator chemotherapies in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. The analysis examined progression-free survival in the intention-to-treat population by HER2-immunohistochemistry status, and the results demonstrated that Trodelvy improved median PFS vs. TPC in both HER2-low and IHC0 groups, Gilead said in a statement. The Trodelvy arm showed median PFS of 6.4 months versys 4.2 months in the TPC arm for HER2-low.
LUNG		Hot Stocks 09:00 EDT Pulmonx announces interim CONVERT Study results for AeriSeal System - Pulmonx announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the collateral ventilation status in 78% of patients who were subsequently treated with Zephyr Valves, the company said in a statement. The AeriSeal System is used to close collateral air channels in a target lung lobe of a patient with severe COPD/emphysema. The CONVERT study uses the AeriSeal System to close collateral air flow. The CONVERT trial is ongoing and full clinical outcomes of BLVR with Zephyr Valves were not reported at this time.